Atlas Trials

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Clinical trial NCT03861481 · COMPLETED

Trial details

NCT number
NCT03861481
Sponsor
UCB Biopharma S.P.R.L.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Start date
2019-03-26
Primary completion
2021-03-31
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.